A phase I/IIa clinical trial that the University of Oxford collaborated on has demonstrated that a T-cell therapeutic HIV vaccine was associated with better control of the virus rebound when antiretroviral therapy (ART) was ...
Nov 4, 2022
0
33
Pfizer-BioNTech said Thursday they will test a combined coronavirus and influenza vaccine, which could potentially pave the way for better inoculation uptake for both illnesses.
Nov 3, 2022
0
23
South Korea had administered more COVID-19 vaccine doses per 100 people than other developed countries by the end of March 2022. A new article published in OMICS: A Journal of Integrative Biology presents six pivotal lessons ...
Sep 22, 2022
0
6
A needle-free vaccine patch could better fight COVID-19 variants, such as Omicron and Delta, than a traditional needle vaccine according to a University of Queensland study in mice.
Jul 28, 2022
0
62
German pharmaceutical company CureVac said Tuesday it was suing rival BioNTech for patent infringement over the mRNA technology used to develop the Comirnaty coronavirus vaccine.
Jul 5, 2022
0
2
Most research on immunity to the SARS-CoV-2 virus and COVID-19 vaccine development has focused on antibody responses to the spike protein and other viral surface proteins. But antibodies that recognize the virus's internal ...
Jun 24, 2022
0
154
Rwanda and German pharma company BioNTech broke ground Thursday on Africa's first mRNA vaccine factory where cutting-edge treatments for diseases like COVID-19 will be made for millions across the continent.
Jun 23, 2022
0
2
When COVID-19 created an urgent need for vaccines that could be made quickly, safely and cost-effectively, traditional manufacturing approaches were not sufficient to meet the demand. Biopharmaceutical companies therefore ...
Jun 13, 2022
0
5
British drugmaker GlaxoSmithKline on Tuesday snapped up US biopharmaceutical firm Affinivax for up to $3.3 billion, expanding further into vaccines before the demerger of its consumer health care arm.
May 31, 2022
0
1
A COVID-19 vaccine effective against multiple variants is possible before the end of 2022, the head of US pharmaceutical giant Pfizer said Wednesday.
Apr 13, 2022
0
41
